Definitive Contract 75F40122C00174
Award Date
9/22/22
Potential Completion Date
9/29/23
Potential Value
$291K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $291,618 definitive contract was awarded by the Food and Drug Administration (FDA) to the Institute For Clinical Pharmacodynamics, Inc. (ICPI), a for-profit, minority-owned organization. The contract is in support of the FDA's Combatting Antibiotic Resistant Bacteria (CARB) program and will have a period of performance through September 29, 2023. Under this contract, ICPI will provide pharmacometric analysis and modeling services to the FDA to support updating clinical breakpoints for the...
This is a $263,016.10 firm fixed price prime contract awarded by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) to Institute For Clinical Pharmacodynamics, Inc., a for-profit minority-owned organization. The contract is for the development of modernized susceptibility guidance for the antibiotics ampicillin and vancomycin for Enterococcus species using pharmacometric approaches. The contract has an ultimate completion date of March 29, 2025. The...
This is a $1,904,355.00 definitive cost-no-fee contract awarded by the Food and Drug Administration (FDA), a civilian government agency, to the Institute Of Quantitative Systems Pharmacology, a non-profit organization. The contract is for basic and applied research with two key objectives: (1) to test the hypothesis that variabilities in nanoparticle (NP) properties and tumor targets cause uncertainties in "FORMULA", and (2) to develop computational models to predict the...
<p>This is a $9,671,431.00 Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Safe Health Systems, Inc., a self-certified small disadvantaged business. The contract is for stimulating innovation in clinical evaluations and personalized medicine to improve product development and patient outcome. The contract has no set-aside designation and has an ultimate completion date of March 27, 2026.</p>
The Food and Drug Administration (FDA) awarded a $1,046,568.62 firm-fixed price delivery order to Integrated Behavioral Health, Inc., a for-profit subchapter S corporation, to study the prevalence, experiences, knowledge, and perceptions of falsified and unapproved pharmaceuticals among individuals being assessed for or entering substance use disorder treatment. This delivery order is part of a larger $10 million indefinite delivery contract the FDA has with Integrated Behavioral Health to...
This is a $315,945.00 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Southern Research Institute for "IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY". The contract is a task order under NIAID's larger "In Vitro Antimicrobial Assessments 2011-2018" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The contract does not have a set-aside...
This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...
This is a $137,779 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Institutes For Behavior Resources, Inc., a non-profit organization. The contract supports the FDA's Center for Drug Evaluation and Research Administrative Management Program (OEP) and Human Drugs Program (OCD). The award does not utilize a set-aside designation. Institutes For Behavior Resources, Inc. specializes in providing services related to fatigue risk management, sleep and performance...
This federal contract award, valued at $811,126.00, was issued by the U.S. Food and Drug Administration (FDA) to Digital Medicine Society Inc., a non-profit organization based in Boston, Massachusetts. The contract was awarded under a Broad Agency Announcement (BAA) solicitation for research and development to support the FDA's regulatory science and innovation mission. The contract is a Definitive Contract with a Firm Fixed Price pricing type, and has an ultimate completion date of December 31,...
<p>This is a $580,000.00 Firm Fixed Price contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to F2G LTD, a for-profit organization, on September 29, 2021. The contract is for the creation and validation of a Patient Reported Outcome (PRO) instrument to assess health-related quality of life in patients with coccidioidomycosis. The contract has an ultimate completion date of October 30, 2024 and does not utilize a set-aside designation.</p>